Atossa Therapeutics reports Q3 results
At a glance
- $ATOS today+1.04%last $1.95
- Vs industry peers+2.14 pts6-peer median −1.10% · far ahead
- Since Nov 10−9.72%from the first trade after the story
- 52-week range14.7% above low$1.70 – $14.85
- Cash runway~7 mo$20.6M cash ÷ $2.8M/mo burn · 10-Q
- Coverage0 this week1 in 30 days · too few stories to call a pace
Nothing reported about atossa therapeutics across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: Earnings reports are all about the beat — and what's coming next. A strong number without clear direction can leave investors cold.
- How the stock is trading: $ATOS +1.04% in the latest session.
- Timing: It came out during market hours, so traders could react the same day, and the session move may reflect that.
Where the stock stands
Atossa Therapeutics ($ATOS) gained 1.04% to $1.95 in the latest session. Over the past month it is down 23.8%. That leaves it 87% below its 52-week high of $14.85 and 15% above its low of $1.70, close to the bottom of its range. The year's high was 8.7 times its low, which makes double-digit swings fairly routine here.
What the filings say
In its latest report (10-Q, filed Nov 10, 2026), $ATOS lost $5.6M over the quarter to Sep 30, 2026. Operations used $24.7M of cash over the nine months to Sep 30, 2026 — about $2.8M a month — against $20.6M in cash on Sep 30, 2026. At that pace the cash covers about 7 months, which is why financing, asset sales or restructuring tend to come up for companies in this position. Total liabilities were $4.7M against $20.6M of cash on Sep 30, 2026. The company filed an 8-K — the form for material events — on Nov 10, the same day as this story; it is $ATOS's own account and the first thing to read. Figures are as filed with the SEC; the $ATOS page has the full statements.
How much coverage it is getting
Wook has no other story on Atossa Therapeutics from the last 30 days, so there is no recent run to compare this one with.
The bigger picture
Even if the numbers look good, investors often look past the headline. Guidance and future plans can make or break the mood. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.
What to watch next
The $ATOS page has all the charts, filings, and models. Comparing coverage from different outlets helps spot trends. Wook AI can crunch the numbers — how far $ATOS has come, or how this week's chatter stacks up.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Seeking Alpha published this on November 10, 2026. $ATOS has moved -9.72% ($2.16 to $1.95). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
